Clinical Trials Testing Novel Combinations in Diffuse Large B-Cell Lymphoma
Researchers are conducting phase 2 and 3 trials to investigate novel treatment combinations for patients with DLBCL.
Lymphoma
LYMPHOMA
FEATURE
LATEST NEWS
Adding Ibrutinib to RICE or RVICI Provides No Benefit in Pediatric Rel/Ref B-NHL
Researchers sought to determine whether adding ibrutinib to multiagent chemotherapy would improve survival in pediatric patients with B-NHL.
Adding Bortezomib to DRC Does Not Improve PFS in Waldenström Macroglobulinemia
Researchers sought to determine whether adding bortezomib to DRC would improve survival in patients with Waldenström macroglobulinemia.
Long-Term Follow-Up Confirms Efficacy of N-AVD in Hodgkin Lymphoma
Researchers sought to determine whether N-AVD would continue to show a high response rate in patients with early-stage, unfavorable Hodgkin lymphoma.
New Model Using Ferroptosis-Related Genes Predicts Survival in Diffuse Large B-Cell Lymphoma
Researchers sought to determine the prognostic value of genes related to ferroptosis in DLBCL.
R-MIV Is an Effective Induction Regimen for Patients With Primary Central Nervous System Lymphoma
Researchers sought to determine whether induction with R-MIV would be an effective treatment for primary CNS lymphoma.
Chronotherapy Study Shows Afternoon Regimens Better for Female Patients With DLBCL
A study evaluating the use of chronotherapy for hematologic cancers identifies how the approach can improve outcomes for some patients.
BV-AVD May Improve PET Results Among Some Patients with Hodgkin Lymphoma
Researchers sought to determine whether first-line brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine would yield favorable results in HL.
“Severe4” Predicts Outcomes of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
A prognostic index called “Severe4” can predict outcomes of CAR T-cell therapy in patients with relapsed/refractory DLBCL, a study suggests.
Mantle Cell Lymphoma Younger Trial Shows Survival Improvement in Long-Term Follow Up Study
Researchers sought to evaluate first-line treatment of patients with advanced-stage MCL who were younger than 66 years of age.
CAR-T Therapy Induces Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Researchers sought to conduct a long-term follow-up study of brexucabtagene autoleucel in patients with MCL.
Treatment May Increase Risk of Colorectal Cancer in Hodgkin Lymphoma Survivors
Hodgkin lymphoma patients treated with subdiaphragmatic radiation and/or procarbazine have an increased risk of developing colorectal cancer, a study suggests.
Bone Marrow Biopsies Provide Little Value for Response Assessments in Follicular Lymphoma
Researchers sought to determine the value of bone marrow biopsies in assessing responses for patients with FL.
Elderly Patients With Mantle Cell Lymphoma May Benefit From Rituximab Maintenance
Researchers sought to determine whether rituximab maintenance therapy would have a clinical benefit in elderly patients with mantle cell lymphoma.
Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma
As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
CAR-T Therapy Shows Promise in Primary and Secondary CNS Lymphomas
Researchers sought to determine whether CR rates were improved using CAR-T therapy in patients with central nervous system lymphoma.
Lisocabtagene Maraleucel Improves Health-Related Quality of Life in Large B-Cell Lymphoma
Researchers sought to determine whether lisocabtagene maraleucel would improve health-related quality of life in patients with relapsed/refractory LBCL.
Epcoritamab Shows Promise in Large B-Cell Lymphoma
Researchers sought to determine whether epcoritamab would be an effective treatment among patients with relapsed or refractory large B-cell lymphoma.
Novel Prognostic Model Appears Superior to IPS in Classical Hodgkin Lymphoma
Researchers sought to determine whether a novel clinical prediction model would be able to determine patient prognosis in advanced-stage classical Hodgkin lymphoma.
Polatuzumab Vedotin Combined With Chemoimmunotherapy Is Provisionally Cost-Effective in Untreated Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether pola-R-CHP would be cost-effective compared with R-CHOP for first-line treatment of DLBCL.
First-Line Nivolumab Shows Promise in Early-Stage, Unfavorable Hodgkin Lymphoma
Researchers sought to determine whether combining nivolumab with chemotherapy and radiotherapy would be effective in early-stage, unfavorable Hodgkin lymphoma.
Outcomes Superior With Peripheral Blood vs Bone Marrow Transplants in PTCL
A retrospective analysis sought to determine safety and tolerability of posttransplantation cyclophosphamide in patients with peripheral T-cell lymphoma.
Odronextamab Appears Safe, Effective in Relapsed/Refractory Follicular Lymphoma
Odronextamab has demonstrated safety and efficacy in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Unmet Need Seen in Patients With B-Cell Lymphoma Who Fail CAR-T Therapy
Researchers sought to determine the unmet need in patients with aggressive B-cell lymphomas whose disease relapses after CAR-T therapy.
High EFS, High Rate of Thrombosis With Crizotinib Plus Chemo in Pediatric ALCL
Crizotinib plus chemotherapy appears effective for pediatric patients with newly diagnosed ALCL, but the combination increases the risk of thrombosis.
CARMEN Regimen Shows Promise in MYC-Rearranged Aggressive Lymphoma
Researchers sought to determine whether the short-term CARMEN would be effective in HIV-positive patients with MYC-rearranged aggressive lymphoma.
Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
Glofitamab Can Provide Lasting Remissions in Heavily Pretreated Large B-Cell Lymphoma
Progression is “uncommon” in patients with relapsed/refractory large B-cell lymphoma who are in complete remission at the end of glofitamab treatment.
Rapcabtagene Autoleucel Shows Activity in Relapsed/Refractory DLBCL
Rapcabtagene autoleucel may elicit durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Adding Ibrutinib to Induction and Maintenance Improves FFS in Mantle Cell Lymphoma
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Zandelisib Plus Zanubrutinib Elicits High ORRs in Relapsed/Refractory FL or MCL
The combination of zandelisib and zanubrutinib produced high overall response rates in patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma.
BTK Inhibitor With CAR T-Cell Therapy Deemed Effective in Relapsed/Refractory MCL
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
Race, Readmission Within 30 Days Increase Sepsis Risk in Cutaneous T-Cell Lymphoma
A single-institution retrospective study identified characteristics of patients with cutaneous T-cell lymphoma at higher risk of sepsis morbidity and mortality.
Tisa-Cel Improves Outcomes Vs Usual Care in Relapsed or Refractory Follicular Lymphoma
Researchers sought to determine whether tisagenlecleucel would improve clinical outcomes compared with usual care among patients with relapsed or refractory FL.
Routine Use of Axicabtagene Ciloleucel Could Be Cost Effective in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether the use of second-line CAR-T therapy could be cost effective in DLBCL.
Consolidation Regimen Deemed “Highly Active” in Relapsed/Refractory Hodgkin Lymphoma
Consolidation with up to 8 cycles of brentuximab vedotin plus nivolumab appears active in high-risk, relapsed/refractory Hodgkin lymphoma.
WBRT May Not Yield Optimal Outcomes in Primary CNS Lymphoma
Researchers sought to determine whether whole brain radiotherapy after induction chemotherapy would improve outcomes in patients with primary CNS lymphoma.
Ibrutinib Improves Survival vs Chemotherapy in CNS-Involved MCL
Researchers sought to determine whether ibrutinib would improve survival outcomes in patients with MCL who had CNS involvement at relapse.
Epcoritamab Granted Priority Review for Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.
Standard of Care More Likely to Be Cost-Effective Than CAR-T Therapy in DLBCL
Researchers sought to determine the cost-effectiveness of CAR-T therapy compared with standard of care in patients with DLBCL.
Elevated MTX Levels Linked With Clinical Outcomes in Lymphoma
Researchers sought to determine whether using high-dose methotrexate would lead to increased risks in patients with lymphoma.
Addition of Atezolizumab to Obinutuzumab-Bendamustine Does Not Improve PFS in Previously Untreated Follicular Lymphoma
Researchers sought to determine whether adding atezolizumab to an obinutuzumab-bendamustine chemoimmunotherapy regimen would improve survival in FL.
Outcomes After BTK Inhibitor Failure in Rel/Ref Mantle Cell Lymphoma
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Consolidative Stem Cell Transplant May Improve Outcomes Among Patients With PTCL
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Adcetris Approved for Pediatric Patients With High Risk Classical Hodgkin Lymphoma
The approval was based on data from the open-label phase 3 AHOD1331 trial.
Lymphoma-Specific Questionnaire Addresses Unmet Patient Needs
Researchers developed an instrument to identify unmet needs and quality-of-life outcomes for patients with lymphoma.
Allo-HSCT May Be Promising Strategy in Relapsed or Refractory PMBCL
Researchers sought to determine whether allo-HSCT would be effective for inducing durable remission among patients with relapsed or refractory PMBCL.
UCBT With FM-Based Reduced-Intensity Conditioning Improved Survival in Lymphoma
Researchers sought to determine whether UCBT with FM-based reduced-intensity conditioning would improve survival outcomes in patients with lymphoma.
Ultra-Low-Dose Radiation Appears Effective in Orbital Indolent B-Cell Lymphoma
Response-adapted ultra-low-dose radiation therapy demonstrated efficacy and negligible toxicity in orbital indolent B-cell lymphoma.
PD-L1 and YWHAZ Expression Linked to Prognosis in Diffuse Large B-Cell Lymphoma
Researchers sought to identify links between the expression of 2 proteins and prognosis in patients with diffuse large B-cell lymphoma.
Novel Therapies Present Opportunity to Improve Outcomes for Patients With Richter Transformation
Researchers sought to identify novel therapeutic approaches to patients who develop Richter transformation.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
Loading... 
Loading...